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PTEN is a tumor suppressor gene inactivated in over 30% of human cancers. It encodes a lipid phosphatase that
serves as a gatekeeper of the phosphoinositide 3-kinase signaling pathway. Germline mutation frequently occurs in
this gene in patients diagnosed with PTEN Hamartoma Tumor Syndrome (PHTS). PHTS individuals are characterized
by macrocephaly, benign growth of multiple tissues and increased tumor risk. In addition, autistic phenotypes are
found in 10–20% of individuals carrying the germline PTEN mutation with macrocephaly. In this report, 13 suspected
PHTS patients were screened for mutation in the PTEN gene. A missense variant (c. 302T>C) substituting the isoleu-
cine at codon 101 to a threonine, a single nucleotide insertion (c. 327-328insC) causing a frame shift mutation and
termination at codon 109, and a nonsense variant (c. 1003C>T) truncated the protein at codon 335 were identified.
The I101T mutation significantly reduced PTEN protein expression levels by 2.5- to 4.0-fold. Mechanistically, I101T
reduced the protein half-life of PTEN possibly due to enhanced polyubiquitination at Lysine 13. However, the I101T
mutant retained almost 30% of the lipid phosphatase activity of the wild-type protein. Finally, the I101T mutant has
reduced phosphorylation at a PTEN auto-dephosphorylation site at Threonine 366 and a lowered ratio of nuclear to
cytosolic protein level. These partial losses of multiple PTEN biochemical functions may contribute to the tissue over-
growth and autistic features of this PHTS patient. Autism Res 2018, 0: 000–000. VC 2018 The Authors Autism
Research published by International Society for Autism Research and Wiley Periodicals, Inc.
Lay Summary: The genetics of autism spectrum disorders is highly complex with individual risk influenced by both
genetic and environmental factors. Mutation in the human PTEN gene confers a high risk of developing autistic
behavior. This report revealed that PTEN mutations occurred in 23% of a selected group of Hong Kong patients har-
boring autistic features with gross overgrowth symptoms. Detailed characterization of a PTEN mutation revealed
reduced protein stability as one of the underlying mechanisms responsible for reduced PTEN activity.
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Introduction
The PTEN Hamartoma Tumor Syndrome (PHTS) is a col-
lection of developmental disorders associated with the
mutations in the human PTEN gene localized on chro-
mosome 10q23 [Hansen-Kiss et al., 2017]. PHTS encom-
passes previously described hamartoma conditions
including Cowden syndrome (CS), Bannayan–Riley–
Ruvalcaba syndrome, PTEN-related Proteus syndrome,
and Proteus-like syndrome. PHTS is an autosomal domi-
nant inherited disorder characterized by macrocephaly,
hamartomatous overgrowth of multiple tissues and
increased risk of developing cancers of the breast, thy-
roid, skin, and gastrointestinal tract. In fact, more than
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90% of individuals with CS have clinical manifestations
by the late second decade and have an 85% lifetime
risk of developing breast cancer [Zbuk & Eng, 2007]. In
terms of prevalence, it is suggested that the incidence
of CS is approximately 1 in 200,000 [Nelen et al.,
1999], and a combination of inheritance and de novo
mutations in the PTEN gene accounts for some of the
PHTS cases.
Germline mutation in the PTEN gene is found in
approximately 20% of individuals diagnosed with
autism/pervasive developmental disorder with macroce-
phaly [Butler et al., 2005]. Autism spectrum disorder
(ASD) is a neurodevelopmental disorder with a median
age at first diagnosis of 3.8 years of age [Christensen
et al., 2016]. The majority (>80%) of ASD cases has no
known genetic origin with affected individuals showing
impaired social interactions, delayed speech develop-
ment, and sensory hypersensitivity [De Rubeis & Bux-
baum, 2015]. The clinical presentation of ASD is highly
heterogeneous, as reflected in the genetic diversity of
this disorder [Kleijer et al., 2014]. The prevailing view is
that the majority of ASD risk is associated with the
inheritance of common genetic variants, such as single
nucleotide polymorphism or copy number variation.
Only a small fraction of the risk is derived from rare
de novo mutations [Gaugler et al., 2014]. Approximately
80% of ASD occurrences are sporadic and 20% are syn-
dromic. Syndromic ASD patients have autistic features
in addition to a multitude of pathologies associated
with some well-established neurodevelopmental syn-
dromes such as Fragile X (FMR1), Rett (MECP2), Angel-
man (UBE3A), Phelan-McDermid (SHANK3), and PHTS
(PTEN) [O’Roak et al., 2012].
The human PTEN gene encodes a lipid phosphatase
with specificity towards phosphatidylinositol (3,4,5) tri-
phosphate (PIP3) [Parsons, 2004]. In human cancer, the
loss of PTEN functions in epithelial cell types leads to
high PIP3 levels, and this drives diverse protumorigenic
pathways emulating a constitutively active phosphoino-
sitide 3-kinase (PI3-K) [Song, Salmena, & Pandolfi,
2012]. The outcome of PTEN loss in neuronal cell types
is beginning to emerge. Cell type specific deletion of
PTEN gene in neural progenitor cells or postmitotic
neurons in mice resulted in macrocephaly, excessive
dendritic arborization, and autistic features [Groszer
et al., 2001; Kwon et al., 2006].
The mammalian PTEN genes are highly conserved
with an amino (N)-terminal catalytic domain and a car-
boxyl (C)-terminal regulatory C2 domain, which is fol-
lowed by a flexible tail region composed of numerous
sites for posttranslational modifications. The posttrans-
lational modifications of the tail region are implicated
in regulating PTEN catalytic activity, stability and sub-
cellular localization. In PHTS, missense, frameshift and
nonsense variants have been reported to target the
entire coding region of the human PTEN gene [Hansen-
Kiss et al., 2017]. In this report, we characterized PTEN
germline mutations associated with three cases of PHTS
with macrocephaly and neurodevelopmental delays.
Methods
Clinical Cases
Patients with a clinical suspicion of PHTS including
autistic features and/or neurodevelopmental delays and
macrocephaly were referred for assessment and genetic
testing to the Clinical Genetic Service (CGS) of Depart-
ment of Health. The CGS is the only government
funded genetic referral centers that provide comprehen-
sive genetic counseling, diagnostic and laboratory ser-
vice for the whole of Hong Kong population. All
records of patients with suspected PHTS between Janu-
ary 1995 and September 2016 under CGS were retrieved
from the computer database system. A total of thirteen
patients with clinical diagnoses after assessment were
recruited for genetic investigation.
Chemicals
All chemicals were purchased from Sigma Aldrich
unless otherwise indicated.
Antibody Reagents
Antibodies against PTEN (#9552), p-Akt-S473 (#3271),
c-Akt (#9272), PTEN-pS380/pT382/pT383 (#9554) were
from Cell Signaling Inc. The anti-AU5 monoclonal anti-
body (#ab130113) was purchased from Abcam Inc. and
anti-actin antibody (#I-19) was from Santa Cruz Inc. An
antibody directed against PTEN-pT366 has been
described previously [Tibarewal et al., 2012].
PTEN Mutation Analysis
All 9 exons of the PTEN gene were amplified by poly-
merase chain reaction (PCR) from blood DNA followed
by Sanger sequencing as described previously [Li & Sun,
1997; Liaw et al., 1997; Steck et al., 1997]. 20 ng of
genomic DNA was amplified using Q5 high-fidelity
DNA polymerase (New England BioLabs) under the fol-
lowing cycling condition: hot start at 988C, 30 sec, and
25 cycles of 988C, 10 sec, 558C, 30 sec, and 728C, 30
sec. The annealing temperature for exon 1 PCR was
raised to 578C. Each exon was first pre-amplified with
two outside primers (a and b). PCR products were puri-
fied by a PCR Cleanup kit (Geneaid) and eluted with 20
ll of water. DNAs were diluted 60 times and amplified
with a pair of nested primers (c and d). Exon 4 was
amplified once with a primer pair (X4a and X4b) and
sequenced directly with a nested primer (X4c). PCR
products were resolved by agarose gel electrophoresis
and correct size fragments were isolated by a Gel Extrac-
tion Kit (Geneaid). DNA fragments were sequenced
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with the nested primers. Mutations detected will be
confirmed with an independent round of PCR reaction
and resequencing of the opposite strand.
Exon1: X1a cagccgttcggaggatta, X1b atatgacctagcaa
cctgacca
X1c gttttcccagtcacgacgagtcgctgcaaccatcca, X1d agg
aaacagctatgaccatctaagagagtgacagaaaggta
Exon2: X2a ccatgtggaagttacctttta, X2b tacggtaagcca
aaaaatga
X2c gttttcccagtcacgacgtgaccaccttttattactcca, X2d ag
gaaacagctatgaccatagtatctttttctgtggctta
Exon3: X3a atattctctgaaaagctctgg, X3b ttaatcggtttag
gaatacaa
X3c gttttcccagtcacgacgatagaaggggtatttgttgga, X3d
aggaaacagctatgaccatcctcactctaacaagcagata
Exon4: X4a gttaaacacagcataatatgtgtc, X4b tatgtatct-
cactcgataatctgg, X4c ctcactcgataatctggatgactc
Exon5: X5a agtttgtatgcaacatttctaa, X5b ttacttgtcaat
tacacctca
X5c gttttcccagtcacgacggcaacatttctaaagttaccta, X5d
aggaaacagctatgaccatctgttttccaataaattctca
Exon6: X6a atatgttcttaaatggctacga, X6b ctttagcccaa
tgagttga
X6c gttttcccagtcacgacgagttaccatagcaatttagtga, X6d
aggaaacagctatgaccataatttgttcaaatgcttcaga
Exon7: X7a acagaatccatatttcgtgta, X7b taatgtctcac
caatgcca
X7c gttttcccagtcacgacgatcgtttttgacagtttg, X7d aggaa
acagctatgaccattcccaatgaaagtaaagtaca
Exon8: X8a tgcaaatgtttaacataggtga, X8b cgtaaacact
gcttcgaaata
X8c gttttcccagtcacgacgaggtgacagattttctttttta, X8d
aggaaacagctatgaccatagctgtactcctagaatta
Exon9: X9a cctcttaaaagatcatgtttg, X9b agattggtca
ggaaaagagaa
X9c gttttcccagtcacgacggttcatctgcaaaatgga, X9d agga
aacagctatgaccatggtaatctgacacaatgtccta
Expression Plasmids
The I101T, D109X, K13E, K289E, I101T/K289E, and
I101T/K13E mutants were generated by PCR-based site-
directed mutagenesis. All cDNAs generated were cloned
into either the pEF-AU5 or pEGFP-C1 vector and authen-
ticity confirmed by sequencing analysis as described pre-
viously [Kimmelman, Nunez Rodriguez, & Chan, 2002].
The wild-type (WT) and D92A/C124A (DCAT) catalytic
dead expression plasmids have been described before
[Odriozola, Singh, Hoang, & Chan, 2007; Singh, Odrio-
zola, Guan, Kennedy, & Chan, 2011].
Cell Cultures
The HEK293T, PC3, and U251 cell lines were from the
cell bank at the National Cancer Institute, USA. Cul-
tures were maintained in DMEM supplemented with
10% fetal bovine serum (FBS) and penicillin-
streptomycin (pen-strep) mixture manufactured by Life
Technologies. For transfection of cells, approximately
1 3 105 cells were seeded in a well of a 6-well culture
dish. 0.1 to 3.0 lg of plasmids was co-incubated with 2
ll of Lipofectamine 2000 in 0.2 ml of Opti-MEM (Life
Technologies). This mixture was added to 2 ml of
DMEM15% FBS medium without pen-strep and incu-
bated for 16 hr. Cells were processed 24–48 hr later.
Lipid Phosphatase Assay
An immunoprecipitation-coupled lipid phosphatase
assay was performed as previously described [Singh,
Odriozola, Guan, Kennedy, & Chan, 2011]. Briefly, 3 3
105 293T cells in 100-mm plates were transfected by lip-
ofection using 10 lg of various PTEN expression con-
structs. After 36 hr, cells were washed twice with cold
TBS (25 mM Tris-HCl pH8.0, 150 mM NaCl) and solubi-
lized in 550 ll of lysis buffer (25 mM Tris-HCl pH8.0,
150 mM NaCl, 1% Triton X-100, 2 mM DTT, and a pro-
tease inhibitor cocktail). The entire lysate was subjected
to immunoprecipitation with 1 lg of an anti-AU5 epi-
tope antibody for 3 hr at 48C. The antibody bound
PTEN protein was captured with 35 ll of GammaBind G
sepharose beads (GE Healthcare Life Sciences) for 1 hr.
Reactions were initiated with the addition of 30 ll of
reaction mixture (25 mM Tris-HCl pH8.0, 10 mM DTT,
50 lM PIP3 and 50 lM PIP2) (Echelon). After incubating
at 378C for 10 min, 100 ll of Malachite green (Echelon)
was added to 25 ml of each reaction mixture. The absor-
bance at OD 620 nm was measured in an xMark Micro-
plate Absorbance Spectrophotometer (Bio-Rad). The
amount of PTEN protein assayed was quantified using
purified glutathione S-transferase (GST)-PTEN fusion
protein as a standard. The enzymatic activity was pre-
sented as pmol PPi released/ng/min of PTEN.
Western Blotting Analysis
Cells were routinely solubilized in 100 ll of either 23
Laemmli buffer or RIPA buffer composed of 50 mM
Tris-HCl pH7.5, 1% Triton X-100, 0.5% sodium deoxy-
cholate, 0.1% SDS, 150 mM NaCl, 10 mM MgCl2, and
protease and phosphatase inhibitors. Approximately 5–
20 lg of total cell lysates was resolved on 10% SDS-
PAGE gels, protein species were transferred onto nitro-
cellulose membranes and probed with selected primary
antibodies. Bound antibodies were detected with either
horseradish peroxidase-conjugated anti-mouse or rabbit
secondary antibodies. The expression levels of protein
were visualized by the standard ECL method (Life Tech-
nologies) followed by exposure to X-ray films. Band
intensity was quantified by the GS-900 Calibrated Den-
sitometer System (Bio-Rad).
Immunofluorescence Analysis
Cells were seeded with a density of 1 3 104 on a glass
coverslip coated with 0.5% MatrigelVR Matrix (CORNING
#356231), in a 12-well-plate. Cells were transfected with
0.5 lg of DNA and 1 ll of Lipofectamine 2000 for 6 hr
INSAR Wong et al./PTEN mutations in Hong Kong patients 3
in DMEM without pen-strep. After 36 hr, cells were
fixed with 4% paraformaldehyde for 15 min and per-
meabilized with 0.5% of Triton X-100 in PBS for 12
min at room temperature (RT). Permeabilized cells were
incubated with 0.1% glycine and then blocked with 5%
FBS in PBS. After blocking, cells were incubated with
anti-AU5 (1:100) at 48C overnight. Cells were washed
with PBS and then incubated with Alexa FluorVR 488
conjugated donkey anti-mouse IgG (H1L) antibody
(1:200) (Life Technologies) for 1 hr. The cells were incu-
bated with 300 nM DAPI and mounted on glass slides
with mounting medium (VECTOR laboratories). Cells
were imaged on a confocal microscope (Olympus
FV1200 SIM) using a 603 silicon oil objective. Focal
planes with the nuclear diameter at its widest were
selected for imaging analysis. The fluorescence signals
of nucleus and cytosol were measured by ImageJ soft-
ware and calculated by the formula: Integrated density
of the chosen compartment2background fluorescence
signal. The relative ratios of nucleus to cytosol intensity
were calculated from 27 cells for each transfected cul-
ture. Separately, EGFP-PTEN was imaged on live cells by
fluorescence microscope (Nikon Ti-E) using the Meta-
Morph imaging software.
Statistical Analysis
Statistical significance was analyzed by Mann–Whitney
test. For multivariant analysis, Two-way ANOVA fol-
lowed by Bonferroni posttest was used. Statistical signif-
icance was considered to be P values of <0.05.
Results
Mutation Analysis of the PTEN Gene in PHTS Patients
A total of 13 genomic DNA samples from patients pre-
senting with PHTS features referred to CGS were
analyzed for PTEN mutations (Table 1). All 9 coding
exons of the human PTEN gene were amplified by PCR
and subjected to Sanger sequencing analysis. Patient
D07018 was a female patient diagnosed at age 9 with
moderate intellectual disability, autistic features, over-
growth and macrocephaly. Sequencing analysis revealed
a T to C transition mutation at nucleotide 302 (c.
302T>C) resulting in a missense mutation altering
codon 101 from an isoleucine to a threonine (Fig. 1).
The authenticity of this mutations was ascertained with
separate PCR reactions and both strands were
sequenced (data not shown). Patient D02373 is a 10-
year-old male patient with developmental delays and
autistic features. The PTEN gene of this patient har-
bored an insertion of a C nucleotide at position 327 (c.
327_328insC) resulting in a shift in the reading frame
and an extension from codon 109 for an additional 4
amino acids (Pro-Met-Ala-Lys) before it terminated at a
stop codon (TGA) (Fig. 1). This resulted in the genera-
tion of a truncated PTEN molecule (denoted here as
D109X) with 113 amino acids in length, and with only
a portion of the catalytic domain being preserved. The
third patient, D09742, was a 10-year-old Chinese boy
referred to CGS for developmental delays, ASD and
macrocephaly (>97th percentile). Clinical examination
showed that he has no dysmorphic feature, goiter or
abnormal skin change. Chromosomal microarray analy-
sis was normal, baseline metabolic workup and MRI
brain scan was normal. Based on the intellectual deficits
and macrocephaly, PTEN mutation was suspected.
Sequencing analysis revealed a c. 1003C>T truncated
mutation at codon R335 (R335X) which resulted in the
deletion of the C-terminal PEST domain and PDZ-
binding motif. Ectopic expression of the D109X mutant
in cultured cells failed to yield any detectable truncated
Table 1. Patient Cases. Patient Identification Numbers, Clinical Features, PTEN Mutation Sites and Origins of Mutation are
Shown
Patient ID Clinical features PTEN mutation Growth parameters
Familial/
De novo
D06035 Mild intellectual disability, overgrowth, autism HC, BH, BW 90–97%
D05214 Autism HC 50%, BH, BW 25–50%
C07087 Macrocephaly, mild intellectual disability, epiphyseal dysplasia HC>97%, BW, BH 50–75%
D08525 Autism, overgrowth HC, BH, BW 90–97%
D02373 Developmental delay, autistic features c. 327 328insC HC>97%, BH, BW 90–97% Familial
D03714 Developmental delay HC, BH, BW 25–50%
D08022 Developmental delay, autistic features HC, BH, BW 10–25%
D03288 Intellectual disability, macrocephaly HC >97%, BW, BH 50–75%
D07018 Moderate intellectual disability, autistic features,
overgrowth, macrocephaly
c. 302T>C HC>97%, BH, BW 90–97% De novo
D10620 Developmental delay HC, BH, BW 25–50%
GS7 Intellectual disability, pigmented macule over penile region HC 50%, BH, BW 25–50%
K10265 Intellectual disability, dysmorphism, strong family history of cancer HC, BH, BW 25–50%
D09742 Macrocephaly, developmental delay, autistic features c. 1003C>T HC >97%, BW, BH 50–75% De novo
HC, head circumference; BW, body weight; BH, body height.
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protein species (data not shown). Also, the C-terminal
truncation mutants similar to R335X have been exten-
sively studied [Sun et al., 2014; Tolkacheva et al., 2001].
Therefore, the I101T mutant was analyzed in greater
details because it has not been extensively
characterized.
The PTEN I101T mutant has reduced protein
expression level
The I101T mutant was tagged in the amino (N)-termi-
nus with an AU5 epitope and ectopically expressed in a
PTEN-null prostate cancer cell line, PC3. As shown in
Figure 2A, the expression level of I101T was reduced by
4-fold when compared to wild-type (WT) or a catalytic-
dead (DCAT) PTEN D92A,C124A mutant (Fig. 2A). Simi-
lar results were also obtained in 293T cells with a 2.5-
fold reduction in protein expression (Fig. 2B). These
results were not due to lowered transfection efficiency
as cotransfection with a GFP plasmid yielded similar
fraction of GFP-positive cells and GFP protein expres-
sion in both PC3 and 293T cells (Fig. S1). The low
expression level suggests that this mutant may be
unstable. To investigate whether I101T has a reduced
protein half-life (t1/2), cells transfected with WT or
I101T expression plasmids were treated with 80 lg/ml
of cycloheximide (CHX) at regular interval for 12 hr.
WT PTEN has a t1/2 of 5.5 hr, while I101T has a signif-
icantly shorter t1/2 of 2 hr (Fig. 2C).
To investigate if altered ubiquitination could be
responsible for the reduced expression of I101T, 293T
cells expressing I101T were treated with 10 lM of
MG132, which is a proteasome inhibitor. I101T has a
3.6-fold increase in basal level of polyubiquitination
(Fig. 3A). MG132 treatment further potentiated the
extent of polyubiquitination by 9.1-fold when com-
pared to WT or the DCAT mutant (Fig. 3A). This result
suggests that I101T may undergo a higher rate of degra-
dation through polyubiquitination. Since both codon
K13 and K289 of PTEN were previously reported to be
ubiquitination sites, they were mutated to generate
I101T/K13E and I101T/K289E double mutants. The
rationale was that the substitutions of these sites could
rescue the degradation of the I101T mutant. Transfec-
tion of the same amount of plasmid DNA into 293T
cells showed that the I101T/K13E double mutant par-
tially restored the I101T level from 32% to 77% of WT
(Fig. 3B). In contrast, the I101T/K289E double mutant
failed to rescue the reduced protein expression of the
I101T mutant. Of note, the K13E mutant was intrinsi-
cally more stable and displayed higher protein expres-
sion level. Next, PTEN levels in whole cell lysates were
normalized and Western blotting was carried out.
Under this condition, I101T showed a higher intensity
of smear above the unmodified 57 kDa PTEN band (Fig.
3C). The higher intensity of smear indicated that a
larger proportion of I101T was polyubiquitinated. For
the double mutants, only the I101T/K13E but not the
I101T/K289E mutant showed a decreased in polyubiqui-
tination (Fig. 3C). Overall, our results indicate that K13
is responsible for the polyubiquitination and degrada-
tion of I101T.
To examine whether the reduced protein expression
was due to changes in protein phosphorylation, the
I101T mutant was expressed in 293T cells and immuno-
precipitated with an anti-AU5 antibody. Due to the
uneven expression of PTEN mutants, the amounts of
lysate were adjusted in order to normalize the level of
PTEN being analyzed. Western blotting analysis using
an anti-phospho-PTEN S380/T382/T383 antibody did
not reveal significant changes in phosphorylation at
these three sites (Fig. 4A). However, probing with an
anti-phospho-PTEN T366 antibody revealed a 4.5-fold
reduction in phosphorylation (Fig. 4B). As expected,
the DCAT mutant, which has been shown to be more
stable than WT, showed a 2.6-fold increase in p-PTEN
T366 level (Fig. 4B). Thus, our data demonstrate that
the I101T mutant has reduced phosphorylation at the
Figure 1. Mutation analysis of PTEN gene. All 9 exons of the
human PTEN gene were amplified and subjected to Sanger
sequencing analysis. A T to C substitution at position 302 of
codon 101 was detected in patient D07018, a C insertion at
position 327–328 of codon 109 in patient D02373, and a C to T
substitution at position 1003 of codon 335 in patient D09742.
Mutation sites are indicated by arrows.
INSAR Wong et al./PTEN mutations in Hong Kong patients 5
T366 site, which may contribute to its reduced protein
expression level.
Lipid Phosphatase Activity of the PTEN I101T Mutant
Codon I101 is located within the phosphatase domain
of PTEN. To examine whether the I101T mutation
could affect PTEN lipid phosphatase activity, both in
vivo and in vitro enzymatic assays were performed. For
the in vivo assay, I101T was ectopically expressed in two
PTEN-null cell lines, PC3 and U251, to determine its
lipid phosphatase activity. As shown in Figure 5A and
B, I101T retained 46% and 75% of the ability of WT in
suppressing p-Akt S473 in PC3 and U251, respectively.
To examine the ability of I101T in suppressing serum-
induced p-Akt, PC3 cells were serum-starved overnight
and stimulated with FBS for 10 min. Under this condi-
tion, I101T still retained most of the capacity in sup-
pressing both p-Akt T308 and p-Akt S473 as compared
to wild-type (Fig. 5C). One caveat of this data is that
the I101T mutant has lower protein expression levels
and the fact that overexpression system was used.
Therefore, in vitro assays were performed by normalizing
the expression level of different PTEN protein species.
In this assay, AU5-tagged PTEN WT, DCAT and I101T
mutants were expressed in 293T and immunoprecipi-
tated with an anti-AU5 epitope antibody. Affinity puri-
fied proteins were then incubated in a reaction mixture
containing PIP31PIP2 for 10 min at 378C and the enzy-
matic activity was expressed as pmol of free phosphate
released per ng of PTEN per min (pmol ng21min21). As
shown in Figure 5D, the I101T mutant retained 30%
of the lipid phosphatase activity of the WT protein. As
expected, the catalytic dead DCAT mutant had the low-
est apparent enzymatic activity. Thus, these results are
consistent with the in vivo assays. We conclude that the
PTEN I101T mutant has a partial loss of lipid phospha-
tase activity and together with the reduced protein
expression, contribute to the symptoms observed in
this patient.
The PTEN I101T Mutant Has Decreased Nuclear
Localization
PTEN is known to associate with microvesicles in the
cytoplasm [Naguib et al., 2015] and its nuclear localiza-
tion is linked to its role in genomic stability [Shen
et al., 2007; van Ree, Nam, Jeganathan, Kanakkanthara,
& van Deursen, 2016]. To test whether the PTEN I101T
mutant has altered subcellular distribution, immunoflu-
orescence analysis was conducted using an anti-AU5
monoclonal antibody. As shown in Fig. 6A, AU5-tagged
PTEN has an overall greater staining intensity in the
cytoplasm than in the cell nucleus. The I101T mutant
as well as the DCAT mutant showed a 75% decrease in
nuclear/cytosol (N/C) distribution when compared with
Figure 2. Expression analysis of PTEN I101T mutant. (A) Indicated expression plasmids were transfected in PC3 cells. After 48 hr,
cells were solubilized with Laemmli buffer. Western blotting analysis was carried out using anti-PTEN and anti-actin antibodies. (B)
Similar experiments were conducted in 293T cells with comparable results being obtained. Results were quantified from six indepen-
dent experiments. Bars, SD. **P< 0.01; Mann–Whitney test. (C) 293T cells were transfected with either WT or I101T expression plas-
mids. Cells were treated with cycloheximide (80 lg/ml) for the indicated durations. Cells were solubilized in Lammeli buffer and the
levels of PTEN were determined by Western blotting analysis and normalized to actin levels. Results from three independent experi-
ments were quantified. Bars, SD. **P< 0.01; Two-Way ANOVA with Bonferroni posttest.
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WT (Fig. 6A). To confirm this finding, GFP-tagged PTEN
WT or I101T were expressed in 293T. Analyzing the N/
C distribution also revealed a decrease in N/C ratio by
approximately 55% of the I101T mutant (Fig. 6B). This
data suggests that the PTEN I101T mutant may have its
nuclear functions compromised.
Discussion
The 13 patients in our cohort have clinical features of
autism and macrocephaly. The PTEN mutation fre-
quency of 23% (3/13) resembles the one reported by
Butler et al. from a subset of individuals with ASD and
Figure 4. Phosphorylation state of PTEN I101T mutant. Western blot analysis of 293T cells transfected with WT, DCAT and I101T.
Similar level of PTEN was immunoprecipitated with an anti-AU5 antibody and Western blotting analysis was carried out with
either an anti-p-PTEN S380/T382/T383 (p-3P) (A) or an anti-p-PTEN T366 (B) antibodies. Results were derived from six
independent experiments for (A) and seven individual experiments for (B). Bars, SD. **P< 0.01; ***P< 0.001; ns, not significant;
Mann–Whitney test.
Figure 3. Enhanced polyubiquitination of PTEN I101T mutant. (A) Western blotting analysis of whole cell extracts of 293T trans-
fected with the indicated expression plasmids. Cells were treated with (1) or without (2) 10 lM of MG132 for 6 hr. The intensity
of the polyubiquitinated (PolyUb) PTEN protein species (bracketed) was quantified and normalized to the levels of the unmodified
PTEN. Results derived from six independent experiments. Bars, SD. *, P< 0.05; **P< 0.01; ns, not significant; Mann–Whitney test.
(B) Western blotting analysis was carried out as outlined in (A) and the relative expression of PTEN was quantified and normalized
to actin. Results from six independent experiments. Bars, SD. **P< 0.01; ns, not significant; Mann–Whitney test. (C) Similar lysates
were first normalized to give similar PTEN expression and Western blotting analysis was performed using anti-PTEN antibody to
detect the extent of polyubiquitination. The non-ubiquitinated PTEN protein species are marked with an asterisk.
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extreme macrocephaly [Butler et al., 2005]. It is also
interesting to note that only 25% of PHTS subjects have
pathologic germline mutations in the PTEN gene
[Ngeow & Eng, 2016; Tan et al., 2011]. Therefore, the
genetic basis of a significant fraction of PHTS still
remained to be uncovered. There are several possibili-
ties. First, a host of posttranslational modifications such
as phosphorylation, ubiquitination, acetylation, and
SUMOylation can suppress PTEN catalytic activity and
subcellular localization [Singh & Chan, 2011]. Alterna-
tively, The PTEN promoter region can be subjected to
epigenetic silencing [Salvesen et al., 2001]. Similarly,
PTEN gene expression can be reduced posttranscription-
ally by microRNAs [Meng et al., 2007]. Also, individual
exons can be deleted entirely rendering detection by
conventional Sanger sequencing not feasible. The use of
next generation sequencing approaches may resolve
this issue. In this cohort, 2 out of 3 cases with PTEN
mutations are de novo change (Table 1). Along this line,
a study of 187 pathogenic PTEN-positive families led to
an estimate that the frequency of de novo PTEN muta-
tion is between 10.7% and 47.6% [Mester & Eng, 2012].
The I101T mutant revealed in our cohort has previ-
ously been identified from a Cowden Disease cohort of
3,042 probands [Tan et al., 2011; Vanderver et al.,
2014]. Separately, Medne et al. had reported the same
mutation in a patient with macrocephaly and hypoto-
nia but with normal speech and cognitive development
(http://www.ashg.org/genetics/ashg07s/f21147.htm). A
survey of the COSMIC database revealed ten human
cancers that harbored the I101T mutation: eight cases
of gliomas [James et al., 1999; Sasaki et al., 2001;
Schmidt et al., 1999], one case of lymphoid neoplasm
and one case of colorectal cancer.
As for the biochemical properties of the I101T
mutant, the major mechanism of PTEN inactivation is
the 2.5 to 4-fold or on an average 70% reduction in its
protein expression when compared with WT. In con-
junction with a 70% decrease in lipid phosphatase
activity in the I101T mutant, we estimated that this
patient retains 21% of the total PTEN catalytic func-
tion. Since patient D07018 harbors a wild-type allele, it
is expected that each somatic cell still possesses 71%
of PTEN catalytic activity. Similarly, decreased in pro-
tein stability has been reported with other ASD PTEN
mutants [Spinelli, Black, Berg, Eickholt, & Leslie, 2015].
Recent detailed biochemical analysis of PTEN phosphor-
ylation site mutants revealed that phosphorylation at
T366/S370 occludes the catalytic pocket of PTEN with-
out affecting its liposome binding capacity [Masson,
Figure 5. Lipid phosphatase activity of PTEN I101T mutant. Empty vector control (C), PTEN WT and I101T expression plasmids were
transfected in either PC3 (A) or U251 (B) cell lines. The levels of p-Akt S473 (p-Akt) and total Akt (c-Akt) were examined by West-
ern blotting analysis. Specific p-Akt levels were calculated from six and three individual experiments for PC3 and U251, respectively.
Bars, SD. *P< 0.05; **P< 0.01; ns, not significant; Mann–Whitney test. (C) PC3 transfected with indicated plasmids were serum-
starved for overnight and stimulated with 10% FBS for 10 min. The levels of p-Akt T308, p-Akt S473 and total Akt (c-Akt) were
examined by Western blotting analysis. Specific p-Akt levels were calculated from three individual experiments. ns, not significant;
Mann–Whitney test. (D) Indicated plasmids were transfected in 293T cells. PTEN was immunoprecipitated by an anti-AU5 antibody
and probed with an anti PTEN antibody (lower panel). PTEN protein levels were normalized and lipid phosphatase assay was carried
out with PIP21PIP3 as substrates with released phosphate measured by a Malachite Green Assay kit (Echelon). Lipid phosphatase
activities from seven independent experiments were quantified and expressed as pmol ng21min21. Bars, SD. **P< 0.01,
***P< 0.001; Mann–Whitney test.
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Perisic, Burke & Williams, 2016]. It was paradoxical that
the reduced p-T366 in I101T mutant was associated with
a reduction in lipid phosphatase activity towards soluble
PIP3. There are two plausible explanations. First, there are
other phosphorylation sites in the C-terminal PEST
domain of PTEN that could be altered in the I101T
mutant to reduce its intrinsic phosphatase activity. These
include S362, S370, S380, T382, T383, S385, S370, and
T398 [Singh & Chan, 2011; Fragoso & Barata, 2015]. Sec-
ond, codon I101 is located in the alpha-helical structure
of the pa3 region [Lee et al., 1999]. It is unlikely to be
involved in the direct interaction with lipid or protein
substrates such as those encompassing codon 120–130.
However, the isoleucine to threonine substitution may
distort the catalytic pocket leading to compromised sub-
strate binding or catalytic activity.
The 4.5-fold reduction in p-T366 of the I101T mutant
also correlated with a destabilization of PTEN protein.
T366 is phosphorylated by both Gsk3-b and Plk3, which
can have either a destabilizing or stabilizing role,
respectively [Maccario, Perera, Davidson, Downes, &
Leslie, 2007; Xu et al., 2010]. Currently, it is unclear if
the reduced I101T protein expression is caused by
reduced p-T366 level. Generating a I101T/T366E
mutant to mimic constitutive phosphorylation of T366
may resolve this issue. Our results have indicated that
K13 is critically important in the polyubiquitination
and stability of the I101T mutant. The first cancer-
associated mutant of K13, K13E, was identified in a
human glioblastoma sample [Duerr et al., 1998]. The
K13E mutant fails to bind plasma membrane and has
attenuated ability to translocate to the cell nucleus [Gil
et al., 2006; Trotman et al., 2007; Walker, Leslie, Perera,
Batty, & Downes, 2004]. Indeed, K13 is polyubiquinti-
nated and implicated in protein stability, while K289 is
preferentially mono-ubiquitinated and plays a role in
nuclear targeting [Trotman et al., 2007]. Therefore, it is
not surprising that the I101T/K13E mutant but not the
I101T/K289E mutant has restored protein expression.
How heightened polyubiquitination at K13 in the
I101T mutant can perturb nuclear localization is cur-
rently not clear.
It is also important to note that partial reduction
rather than complete loss of PTEN phosphatase activity
may be a defining feature of ASD-associated PTEN
mutants, which has been reported by two groups previ-
ously [Rodriguez-Escudero et al., 2011; Spinelli et al.,
2015]. Indeed, it is estimated that patient D07018
retains 71% of wild-type PTEN catalytic activity. Either
neural cell types are hypersensitive to modest PTEN
loss or additional genetic variations are in play to cause
the clinical symptoms in PHTS patients. Eventually,
there is a need to examine if the extent of loss in PTEN
activity in target cells shows correlation with disease
severity not only in PHTS patients but also in idio-
pathic ASD.
Figure 6. Nuclear localization of PTEN I101T mutant. (A) Immunofluorescence analysis of AU5-tagged PTEN WT, DCAT, and I101T
in 293T using an anti-AU5 antibody and detected with an anti-mouse IgG antibody conjugated with Alexa 488 fluorophore. Cell
nuclei were stained with DAPI. Positive control for nuclear staining was provided by a PTEN tagged with a nuclear localization signal
(NLS-WT). Fluorescent signals were captured by confocal microscopy and representative images are shown. Fluorescent intensity was
quantified for the cytosolic and nuclear compartments by ImageJ software and expressed as a relative ratio. Bars, SD; n5 27;
***P< 0.001. ns, not significant. One-way ANOVA. (B) Live cell imaging of GFP-PTEN WT and GFP-PTEN I101T; nuclei were stained
with Hoechst 33342. Fluorescent intensity was quantified for the cytosolic and nuclear compartments and expressed as a ratio of
the nuclear to cytosol fluorescence intensity. Bars, SD. n5 7, ***P< 0.001. Mann–Whitney test.
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We have observed reduced nuclear localization of the
I101T mutant. PTEN has been implicated in chromo-
some stability through binding to centromeric protein
CENPC-C [Shen et al., 2007] as well as Dlg1 which is
involved in mitotic spindle pole movement [van Ree,
Nam, Jeganathan, Kanakkanthara, & van Deursen,
2016]. Moreover, PTEN together with p53, can regulate
gene transcription under genotypic stress conditions [Li
et al., 2006]. The role of nuclear PTEN in ASD is not
defined. Indeed, we have also analyzed the nuclear
localization of several ASD-associated PTEN mutants
and found both increased and decreased nuclear locali-
zation (manuscript in preparation). Whether altered
phosphorylation or SUMOylation of the I101T can
affect nuclear localization is not clear at present. Future
research into understanding the transcriptome of neu-
ronal cells carrying specific ASD-associated PTEN
mutant may provide molecular insights into the disease
mechanisms of ASD.
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Figure S1. Transfection efficiency of PC3 and 293T
cells. (A) PC3 and (B) 293T cells were cotransfected
with 0.5 mg PTEN and 0.3 mg pEGFP (GFP) expression
plasmids. Cells were solubilized after 24 hr and fluores-
cent images from five random fields were counted for
the number of green cells and expressed at fraction of
GFP1 cells. The expression levels of PTEN and GFP are
shown in the bottom panels.
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